

10/041,574

8/12/04

**Listing of claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-24. (Cancelled)

25. (Previously presented) An isolated antibody or fragment thereof that binds to a protein selected from the group consisting of:

- (a) a protein consisting of amino acid residues from about 116 to about 271 of SEQ ID NO:2;
- (b) a protein consisting of amino acid residues from about 283 to about 308 of SEQ ID NO:2;
- (c) a protein consisting of amino acid residues from about 336 to about 372 of SEQ ID NO:2;
- (d) a protein consisting of amino acid residues from about 393 to about 434 of SEQ ID NO:2;
- (e) a protein consisting of amino acid residues from about 445 to about 559 of SEQ ID NO:2; and
- (f) a protein consisting of amino acid residues from about 571 to about 588 of SEQ ID NO:2.

26. (Previously presented) The antibody or fragment thereof of claim 25 that binds protein (a).

27. (Previously presented) The antibody or fragment thereof of claim 25 that binds protein (b).

28. (Previously presented) The antibody or fragment thereof of claim 25 that binds protein (c).

29. (Previously presented) The antibody or fragment thereof of claim 25 that binds protein (d).

30. (Previously presented) The antibody or fragment thereof of claim 25 that binds protein (e).

~~31.~~ 7 (Previously presented) The antibody or fragment thereof of claim ~~25~~ that binds protein (f).

~~32.~~ (Cancelled)

~~33.~~ 8 (Previously presented) The antibody or fragment thereof of claim ~~25~~ wherein said protein bound by said antibody or fragment thereof is glycosylated.

~~34.~~ 9 (Previously presented) The antibody or fragment thereof of claim ~~25~~ which is a human antibody.

~~35.~~ 10 (Previously presented) The antibody or fragment thereof of claim ~~25~~ which is a polyclonal antibody.

~~36.~~ 11 (Previously presented) The antibody or fragment thereof of claim ~~25~~ which is selected from the group consisting of:

- (a) a chimeric antibody;
- (b) a humanized antibody;
- (c) a single chain antibody; and
- (d) an Fab fragment.

~~37.~~ 12 (Previously presented) The antibody or fragment thereof of claim ~~25~~ which is labeled.

~~38.~~ 13 (Currently amended) The antibody or fragment thereof of claim ~~25~~ which is radiolabeled.

~~39.~~ 14 (Previously presented) The antibody or fragment thereof of claim ~~25~~ which is biotinylated.

40. (Cancelled)

~~41.~~ 15 (Previously presented) The antibody or fragment thereof of claim ~~25~~, wherein the antibody or fragment thereof agonizes TR9 signaling.

~~42.~~ 16 (Previously presented) The antibody or fragment thereof of claim ~~25~~ which is fused to a heterologous polypeptide.

43. (Previously presented) The antibody or fragment thereof of claim 25 which is attached to a solid support.

44. (Previously presented) The antibody or fragment thereof of claim 25 wherein said antibody or fragment thereof binds to said protein in a Western blot.

45. (Previously presented) The antibody or fragment thereof of claim 25 wherein said antibody or fragment thereof binds to said protein in an ELISA.

46. (Previously presented) An isolated cell that produces the antibody or fragment thereof of claim 25.

47. (Previously presented) A hybridoma that produces the antibody or fragment thereof of claim 25.

48. (Currently amended) A method of detecting TR9 protein in a biological sample comprising:

- (a) contacting the biological sample with the antibody or fragment thereof of claim 25; and
- (b) detecting binding of said antibody or fragment thereof to the TR9 protein in the biological sample.

49. (Previously presented) The method of claim 48 wherein the antibody or fragment thereof is a polyclonal antibody.

50. (Previously presented) An isolated monoclonal antibody or fragment thereof that binds to a protein selected from the group consisting of:

- (a) a protein consisting of amino acid residues from about 116 to about 271 of SEQ ID NO:2;
- (b) a protein consisting of amino acid residues from about 283 to about 308 of SEQ ID NO:2;
- (c) a protein consisting of amino acid residues from about 336 to about 372 of SEQ ID NO:2;
- (d) a protein consisting of amino acid residues from about 393 to about 434 of SEQ ID NO:2;

(e) a protein consisting of amino acid residues from about 445 to about 559 of SEQ ID NO:2; and

(f) a protein consisting of amino acid residues from about 571 to about 588 of SEQ ID NO:2.

51. <sup>25</sup> (Previously presented) The antibody or fragment thereof of claim <sup>30</sup> that binds protein (a).

52. <sup>26</sup> <sup>24</sup> (Previously presented) The antibody or fragment thereof of claim <sup>30</sup> that binds protein (b).

53. <sup>27</sup> <sup>24</sup> (Previously presented) The antibody or fragment thereof of claim <sup>30</sup> that binds protein (c).

54. <sup>28</sup> <sup>24</sup> (Previously presented) The antibody or fragment thereof of claim <sup>30</sup> that binds protein (d).

55. <sup>29</sup> <sup>24</sup> (Previously presented) The antibody or fragment thereof of claim <sup>30</sup> that binds protein (e).

56. <sup>30</sup> <sup>24</sup> (Previously presented) The antibody or fragment thereof of claim <sup>30</sup> that binds protein (f).

57. (Cancelled)

58. <sup>31</sup> <sup>24</sup> (Previously presented) The antibody or fragment thereof of claim <sup>30</sup> wherein said protein bound by said antibody or fragment thereof is glycosylated.

59. <sup>32</sup> <sup>24</sup> (Previously presented) The antibody or fragment thereof of claim <sup>30</sup> which is a human antibody.

60. <sup>33</sup> <sup>24</sup> (Previously presented) The antibody or fragment thereof of claim <sup>30</sup> which is selected from the group consisting of:

- (a) a chimeric antibody;
- (b) a humanized antibody;
- (c) a single chain antibody; and
- (d) an Fab fragment.

~~61.~~ <sup>34</sup> (Previously presented) The antibody or fragment thereof of claim ~~50~~ which is labeled. <sup>24</sup>

~~62.~~ <sup>35</sup> (Previously presented) The antibody or fragment thereof of claim ~~50~~ which is radiolabeled. <sup>24</sup>

~~63.~~ <sup>36</sup> (Previously presented) The antibody or fragment thereof of claim ~~50~~ which is biotinylated. <sup>24</sup>

64. (Cancelled)

~~65.~~ <sup>37</sup> (Previously presented) The antibody or fragment thereof of claim ~~50~~ wherein the antibody or fragment thereof agonizes TR9 signaling. <sup>24</sup>

~~66.~~ <sup>38</sup> (Previously presented) The antibody or fragment thereof of claim ~~50~~ which is fused to a heterologous polypeptide. <sup>24</sup>

~~67.~~ <sup>39</sup> (Previously presented) The antibody or fragment thereof of claim ~~50~~ which is attached to a solid support. <sup>24</sup>

~~68.~~ <sup>40</sup> (Previously presented) The antibody or fragment thereof of claim ~~50~~ wherein said antibody or fragment thereof binds to said protein in a Western blot. <sup>24</sup>

~~69.~~ <sup>41</sup> (Previously presented) The antibody or fragment thereof of claim ~~50~~ wherein said antibody or fragment thereof binds to said protein in an ELISA. <sup>24</sup>

~~70.~~ <sup>42</sup> (Previously presented) An isolated cell that produces the antibody or fragment thereof of claim ~~50~~. <sup>24</sup>

~~71.~~ <sup>43</sup> (Previously presented) A hybridoma that produces the antibody or fragment thereof of claim ~~50~~. <sup>24</sup>

~~72.~~ <sup>44</sup> (Currently amended) A method of detecting TR9 protein in a biological sample comprising:

- (a) contacting the biological sample with the antibody or fragment thereof of claim ~~50~~; and

(b) detecting binding of said antibody or fragment thereof to the TR9 protein in the biological sample.

13. 45 (Currently amended) An isolated antibody or fragment thereof that binds to a protein selected from the group consisting of:

- (a) a protein consisting of amino acid residues from about 116-156 to about 271-311 of the amino acid sequence encoded by the cDNA contained in ATCC Deposit Number 209037;
- (b) a protein consisting of amino acid residues from about 283-323 to about 308-348 of the amino acid sequence encoded by the cDNA contained in ATCC Deposit Number 209037;
- (c) a protein consisting of amino acid residues from about 336-376 to about 372-412 of the amino acid sequence encoded by the cDNA contained in ATCC Deposit Number 209037;
- (d) a protein consisting of amino acid residues from about 393-433 to about 434-474 of the amino acid sequence encoded by the cDNA contained in ATCC Deposit Number 209037;
- (e) a protein consisting of amino acid residues from about 445-485 to about 559-599 of the amino acid sequence encoded by the cDNA contained in ATCC Deposit Number 209037; and
- (f) a protein consisting of amino acid residues from about 571-611 to about 588-628 of the amino acid sequence encoded by the cDNA contained in ATCC Deposit Number 209037.

14. 46 45 (Previously presented) The antibody or fragment thereof of claim 13 that binds protein (a).

15. 47 45 (Previously presented) The antibody or fragment thereof of claim 13 that binds protein (b).

16. 48 45 (Previously presented) The antibody or fragment thereof of claim 13 that binds protein (c).

17. 49 45 (Previously presented) The antibody or fragment thereof of claim 13 that binds protein (d).

~~78.~~ <sup>50</sup> (Previously presented) The antibody or fragment thereof of claim ~~73~~ that binds protein (e). <sup>45</sup>

~~79.~~ <sup>51</sup> (Previously presented) The antibody or fragment thereof of claim ~~73~~ that binds protein (f). <sup>45</sup>

80. (Cancelled)

~~81.~~ <sup>52</sup> (Previously presented) The antibody or fragment thereof of claim ~~73~~ wherein said protein bound by said antibody or fragment thereof is glycosylated. <sup>45</sup>

~~82.~~ <sup>53</sup> (Previously presented) The antibody or fragment thereof of claim ~~73~~ which is a human antibody. <sup>45</sup>

~~83.~~ <sup>54</sup> (Previously presented) The antibody or fragment thereof of claim ~~73~~ which is a polyclonal antibody. <sup>45</sup>

~~84.~~ <sup>55</sup> (Previously presented) The antibody or fragment thereof of claim ~~73~~ which is selected from the group consisting of: <sup>45</sup>

- (a) a chimeric antibody;
- (b) a humanized antibody;
- (c) a single chain antibody; and
- (d) an Fab fragment.

~~85.~~ <sup>56</sup> (Previously presented) The antibody or fragment thereof of claim ~~73~~ which is labeled. <sup>45</sup>

~~86.~~ <sup>57</sup> (Previously presented) The antibody or fragment thereof of claim ~~73~~ which is radiolabeled. <sup>45</sup>

~~87.~~ <sup>58</sup> (Previously presented) The antibody or fragment thereof of claim ~~73~~ which is biotinylated. <sup>45</sup>

88. (Cancelled)

~~89.~~ <sup>59</sup> (Previously presented) The antibody or fragment thereof of claim ~~73~~, wherein the antibody or fragment thereof agonizes TR9 signaling. <sup>45</sup>

90. <sup>60</sup> (Previously presented) The antibody or fragment thereof of claim 73 which is fused to a heterologous polypeptide. <sup>45</sup>

91. <sup>61</sup> (Previously presented) The antibody or fragment thereof of claim 73 which is attached to a solid support. <sup>45</sup>

92. <sup>62</sup> (Previously presented) The antibody or fragment thereof of claim 73 wherein said antibody or fragment thereof binds to said protein in a Western blot. <sup>45</sup>

93. <sup>63</sup> (Previously presented) The antibody or fragment thereof of claim 73 wherein said antibody or fragment thereof binds to said protein in an ELISA. <sup>45</sup>

94. <sup>64</sup> (Previously presented) An isolated cell that produces the antibody or fragment thereof of claim 73. <sup>45</sup>

95. <sup>65</sup> (Previously presented) A hybridoma that produces the antibody or fragment thereof of claim 73. <sup>45</sup>

96. <sup>66</sup> (Currently amended) A method of detecting TR9 protein in a biological sample comprising:

- (a) contacting the biological sample with the antibody or fragment thereof of claim 73; and
- (b) detecting binding of said antibody or fragment thereof to the TR9 protein in the biological sample.

97. <sup>67</sup> (Previously presented) The method of claim 96 wherein the antibody or fragment thereof is a polyclonal antibody. <sup>66</sup>

98. <sup>68</sup> (Currently amended) An isolated monoclonal antibody or fragment thereof that binds to a protein selected from the group consisting of:

- (a) a protein consisting of amino acid residues from about 116-156 to about 271-311 of the amino acid sequence encoded by the cDNA contained in ATCC Deposit Number 209037;
- (b) a protein consisting of amino acid residues from about 283-323 to about 308-348 of the amino acid sequence encoded by the cDNA contained in ATCC Deposit Number 209037;

- (c) a protein consisting of amino acid residues from about 336-376 to about 372-412 of the amino acid sequence encoded by the cDNA contained in ATCC Deposit Number 209037;
- (d) a protein consisting of amino acid residues from about 393-433 to about 434-474 of the amino acid sequence encoded by the cDNA contained in ATCC Deposit Number 209037;
- (e) a protein consisting of amino acid residues from about 445-485 to about 559-599 of the amino acid sequence encoded by the cDNA contained in ATCC Deposit Number 209037; and
- (f) a protein consisting of amino acid residues from about 571-611 to about 588-628 of the amino acid sequence encoded by the cDNA contained in ATCC Deposit Number 209037.

99.<sup>69</sup> (Previously presented) The antibody or fragment thereof of claim ~~98~~<sup>68</sup> that binds protein (a).

100.<sup>70</sup> (Previously presented) The antibody or fragment thereof of claim ~~98~~<sup>68</sup> that binds protein (b).

101.<sup>71</sup> (Previously presented) The antibody or fragment thereof of claim ~~98~~<sup>68</sup> that binds protein (c).

102.<sup>72</sup> (Previously presented) The antibody or fragment thereof of claim ~~98~~<sup>68</sup> that binds protein (d).

103.<sup>73</sup> (Previously presented) The antibody or fragment thereof of claim ~~98~~<sup>68</sup> that binds protein (e).

104.<sup>74</sup> (Previously presented) The antibody or fragment thereof of claim ~~98~~<sup>68</sup> that binds protein (f).

105. (Cancelled)

106.<sup>75</sup> (Previously presented) The antibody or fragment thereof of claim ~~98~~<sup>68</sup> wherein said protein bound by said antibody or fragment thereof is glycosylated.

107. (Previously presented) The antibody or fragment thereof of claim 98 which is a human antibody.

108. (Previously presented) The antibody or fragment thereof of claim 98 which is selected from the group consisting of:

- (a) a chimeric antibody;
- (b) a humanized antibody;
- (c) a single chain antibody; and
- (d) an Fab fragment.

109. (Previously presented) The antibody or fragment thereof of claim 98 which is labeled.

110. (Previously presented) The antibody or fragment thereof of claim 98 which is radiolabeled.

111. (Previously presented) The antibody or fragment thereof of claim 98 which is biotinylated.

112. (Cancelled)

113. (Previously presented) The antibody or fragment thereof of claim 98, wherein the antibody or fragment thereof agonizes TR9 signaling.

114. (Previously presented) The antibody or fragment thereof of claim 98 which is fused to a heterologous polypeptide.

115. (Previously presented) The antibody or fragment thereof of claim 98 which is attached to a solid support.

116. (Previously presented) The antibody or fragment thereof of claim 98, wherein said antibody or fragment thereof binds to said protein in a Western blot.

117. (Previously presented) The antibody or fragment thereof of claim 98, wherein said antibody or fragment thereof binds to said protein in an ELISA.

118. <sup>86</sup> (Previously presented) An isolated cell that produces the antibody or fragment thereof of claim 98. <sup>68</sup>

119. <sup>87</sup> (Previously presented) A hybridoma that produces the antibody or fragment thereof of claim 98. <sup>68</sup>

120. <sup>88</sup> (Currently amended) A method of detecting TR9 protein in a biological sample comprising:

- (a) contacting the biological sample with the antibody or fragment thereof of claim 98; and
- (b) detecting binding of said antibody or fragment thereof to the TR9 protein in the biological sample.

121-125. (Cancelled)